Assessment of the economic impact of belimumab for the treatment of systemic lupus erythematosus in the Italian setting: A cost-effectiveness analysis

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Pierotti, Francesca ^a   Palla, Ilaria ^a   Treur, Maarten ^b   Pippo, Lara ^c,d   Turchetti, Giuseppe ^a  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b PHARMERIT INTERNATIONAL   (Netherlands)

^c GSK   (Italy)

^d Amgen   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG COST; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; IMMUNE SYSTEM; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; PROBABILITY; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; COST BENEFIT ANALYSIS; ECONOMICS; ITALY; LUPUS ERYTHEMATOSUS, SYSTEMIC; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVEYS AND QUESTIONNAIRES;

EID: 84949480267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140843     Document Type: Article

References (53)

1. Turchetti G, Yazdany J, Palla I, Yelin E, Mosca M. SLE and the economic perspective: a systematic literature review and points to consider. Clinical and Experimental Rheumatology. 2012; 30(Suppl73): S116-S122.
2. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman D et al. Mortality in systemic lupus erythematosus. Arthritis & Rheumatism. 2006; 54(8): 2550-2557.
3. Nossent J, Cikes N, Kiss E, Pokorny G, Vlachoyiannopoulos P, Olesinska M et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus. 2007; 16(5): 309-17. PMID: 17576731
4. Souza DC, Santo AH, Sato EI. Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis. J Rheumatol. 2012; 39(3): 496-503. doi: 10.3899/jrheum.110241 PMID: 22247362
5. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford). 2012; 51(3): 491-8.
6. Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DDet al. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005; 32(8): 1467-72. PMID: 16078321
7. Zen M, Bassi N, Nalotto L, Canova M, Bettio S, Gatto M et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol. 2012; 30(6):856-63. PMID: 22765883
8. Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1999; 42(12):2682-8. PMID: 10616018
9. Agmon-Levin N, Mosca M, Petri M, Schoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmunity Reviews. 2012; 11:593-595. doi: 10.1016/j.autrev.2011.10.020 PMID: 22041578
10. Mosca M, Bombardieri S, Carmona L. Assessment of multiple organ systems in systemic lupus erythematosus. What will the new guidelines mean? International Journal of Clinical Rheumatology. 2010; 5: 291-297.
11. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey Ret al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Annals of the Rheumatic Diseases. 2010; 69:1269-1274. doi: 10.1136/ard.2009.117200 PMID: 19892750
12. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Cervera Ret al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmunity Reviews. 2011; 10: 383-388. doi: 10.1016/j.autrev.2010.12.008 PMID: 21224016
13. Mosca M, Tani C, Carli L, Bombradieri S. Glucocorticoids in systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2011; 29(Suppl 68): S126-S129.
14. Nossent J, Cikes N, Kiss E, Marchesoni A, Nassonova V, Mosca M. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus. 2007; 16:309-317. PMID: 17576731
15. Nossent J, Kiss E, Rozman B, Vlachoyiannopoulos P, Olesinska M, Marchesoni A et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2010; 19: 949-956. doi: 10.1177/0961203310366572 PMID: 20375124
16. Mosca M, Boumpas DT, Bruce IN, Cervera R, Czirjak L, DörnerT et al. Treat-to-target in systemic lupus erythematosus: where are we today? Clinical and Experimental Rheumatology. 2012; 30(Suppl 73): S112-S115.
17. Doria A, Amoura Z, Cervera R, Khamastha MA, Schneider M, Richter J et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Annals of the Rheumatic Diseases. 2014; 73(1):154-60. doi: 10.1136/annrheumdis-2012-202443 PMID: 23264339
18. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberget DA et al. Total costs and predictors of costs in patients with Systemic Lupus Erythematosus. Rheumatology. 2001; 40: 37-47. PMID: 11157140
19. Meacock R, Dane N, Harrison MJ. The human and economic burden of Systemic Lupus Erythematosus. A systematic review, Pharmacoeconomics. 2013; 31:49-61. doi: 10.1007/s40273-012-0007-4 PMID: 23329592
20. Kotler P, Shalowitz J, Stevens RS, Turchetti G. Marketing perlasanità. Logicheestrumenti. Milano: The McGraw Hill; 2010.
21. Turchetti G, Spadoni E, Geisler EE. Health technology assessment. Evaluation of biomedical innovative technologies. IEEE Engineering in Medicine and Biology Magazine. 2010; 29:70-76. doi: 10.1109/MEMB.2010.936553 PMID: 20659860
22. Mathieu A, Doria A, Perna A, Porcasi R, Garofano A, Maurel F, Pippo L. The annual direct medical cost of Systemic Lupus Erythematosus (SLE) patients and costs drivers (LUCIE study): Italian results. Poster 9th HTA international Annual Meeting. Bilbao, 25th-27th June 2012.
23. Turchetti G, et al. Valutazione dell'impatto clinico ed economico dell'introduzione di belimumab: analisi di costo efficacia. In: De Waure C et al. editors. L'impiego di belimumab nel Lupus Eritematoso Siste-mico: risultatidi una valutazione di HTA. Quaderni Italian Journal of Public Health; 2013. pp.91-110.
24. Petri MA, et al. Belimumab, a BLy S-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and-76 studies. Arthritis & Rheumatism 2010; 62(Suppl 10): 452.
25. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al. BLISS-52 Study Group. Efficacy and safety of Belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377: 721-731. doi: 10.1016/S0140-6736(10)61354-2 PMID: 21296403
26. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D et al. A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLy S, in patients with Systemic Lupus Erytematosus. Arthritis & Rheumatism. 2011; 63: 3918-3930.
27. European Agency Medicines, "Benlysta, " 2014. Available: http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/002015/human med 001466.jsp&mid= WC0b01ac058001d124
28. Mitka M. Treatment for lupus first in 50 years, offers modest benefits, hope to patients. JAMA. 2011; 305(17):1754-55. doi: 10.1001/jama.2011.548 PMID: 21540415
29. Watson P, Brennan A, Fang BH, Petri M. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort. Rheumatology (Oxford). 2015; 54(4):623-632.
30. Turchetti G. L'Health Technology Assessment. Riflessioni sulladimensioneesulle implicazioni orga-nizzative. In: Mantovani LG. editor. L'Health Technology Assessment. Principi, concetti, strumenti oper-ativi. Milano: Il Sole 24ore Libri; 2011.
31. Turchetti G, Scalone L, Della Casa Alberighi O, Mosca M, Montella S et al. The rationale of pharmacoe-conomic analysis in rheumatologic indications. Clinical and Experimental Rheumatology. 2012; 30 (Suppl 73): S64-S71.
32. Turchetti G, Pierotti F. Innovazione e sostenibilità. Unafarmacoeconomiaaserviziodel sistemasani-tario. In: Carnevali G, Manzi P, editors. Lineeguida per una nuova governance del sistemasanitario. Roma: Aracne Editore; 2013.
33. Capri S, Ceci A, Terranova L, Merlo F, Mantovani L et al. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Information Journal. 2011; 35:189-201.
34. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. Journal of Rheumatology. 2014; 41(2): 300-309. doi: 10.3899/jrheum.121368 PMID: 24187095
35. Italian Institute of Statistics (ISTAT), 2010. Available: http://www.istat.it/it/archivio/80308.
36. National Tariffs List of outpatient specialist care of the Italian Ministry of Health. Available: http://www. trovanorme.salute.gov.it/renderPdf.spring?seriegu=SG&datagu=28/01/2013&redaz=13A00528&artp= 3&art=1&subart=1&subart1=10&vers=1&prog=001.
37. Furie R. Four-Year Experience With Belimumab, a BLy S-Specific Inhibitor, in Patients With Systemic Lupus Erythematosus (SLE): LBSL02/99 Study.2010. Poster presented at PANLAR 2010; April 25-28, 2010; Santiago, Chile.
38. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002; 45: S5-S12. PMID: 12136405
39. Piscitelli P, Iolascon G, Greco M, Marinelli A, Gimigliano F, Gimigliano R et al. The occurrence of acute myocardial infarction in Italy: a five years analysis of hospital discharge records, Aging Clinical and Experimental Research. 2011; 23: 49-54.
40. Pugliatti M, Sobocki P, Beghi E, Pini S, Cassano GB, Altamura AC et al. Cost of disorders of the brain in Italy, Neurological Sciences 2008; 29: 99-107. doi: 10.1007/s10072-008-0868-7 PMID: 18483707
41. Treur M, Heemstra M. The cost effectiveness of belimumab in treating patients with Systemic Lupus Erythematosus. Technical Report of a health-economic model, 2011.
42. Italian Institute of Social Assistance (INPS), 2008. Available: http://www.inps.it/webidentity/banchedatistatistiche/dipendenti/index.jsp.
43. Baker K, Pope J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology. 2009; 48: 281-284. doi: 10.1093/rheumatology/ken477 PMID: 19153144
44. Dolan P. Modeling valuations for Euro Qol health states. Medical Care. 1997; 35:1095-1108. PMID: 9366889
45. Briggs A, Schulpher M, Claxton K. Decision modeling for health economic evaluation. Oxford: Oxford University Press; 2006.
46. Italian Association of Health Economics (IAHE). Proposta di linee guida per la valutazione economica degli interventi sanitari. Politiche sanitarie 2009. doi: 10.1706/441.5195
47. McCabe C, Claxton K, Culyer AJ.The NICE cost effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008; 26: 733-744. PMID: 18767894
48. Díaz-Cerezo S, García-Aparicio AM, Parrondo J, Vallejo-Aparicio LA. Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain. Farm Hosp. 2015; 39(3):161-170. doi: 10.7399/fh.2015.39.3.8814 PMID: 26005892
49. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al. Efficacy and safety of rituximab in moderately-to severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis & Rheumatism. 2010; 62: 222-233.
50. Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli Set al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clinical and Experimental Rheumatology 2012; 30(Suppl73): S72-S84.
51. Palla I, Trieste L, Tani C, Talarico R, Cortesi PA, Mosca M et al. A systematic literature review of the economic impact of Ankylosing Spondylitis. Clin Exp Rheumatol. 2012; 30: S136-S141. PMID: 23072824
52. Trieste L, Palla I, Fusco F, Tani C, Baldini C, Mosca M et al. The economic impact of gout: a systematic literature review. Clinical and Experimental Rheumatology. 2012; 30(Suppl 73): S145-S148.
53. Trieste L, Palla I, Baldini C, Talarico R, D'Angiolella L, Mosca M et al. Systemic vasculitis: how little we know about their societal and economic burden. Clinical and Experimental Rheumatology. 2012; 30 (Suppl73): S154-S156.